Federman & Sherwood Investigates PolarityTE, Inc. for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
67
Federman & Sherwood Investigates PolarityTE, Inc. for Possible Violations of Federal Securities Laws

OKLAHOMA CITY, June 26, 2018 (GLOBE NEWSWIRE) -- The law firm of Federman & Sherwood has initiated an investigation into PolarityTE, Inc. (“Polarity”) and its officers and directors, with respect to possible violations of federal securities laws.

Polarity is a company that focuses on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences and is headquartered in Salt Lake City, Utah.  Federman & Sherwood’s investigation focuses on whether Polarity’s officers and/or directors breached their fiduciary duties to Polarity’s shareholders.

If you currently own stock in PolarityTE, Inc., have any information to assist in our investigation, or have questions or concerns regarding this notice or your rights or interests in this matter, please contact Federman & Sherwood.  Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.

Robin Hester
FEDERMAN & SHERWOOD
Telephone: (405) 235-1560
Email to: rkh@federmanlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading